Disease progression modeling with temporal realignment: An emerging approach to deepen knowledge on chronic diseases

Hideki Yoshioka; Ryota Jin; Akihiro Hisaka; Hiroshi Suzuki

doi:10.1016/j.pharmthera.2024.108655

Disease progression modeling with temporal realignment: An emerging approach to deepen knowledge on chronic diseases

Pharmacol Ther. 2024 May 4:259:108655. doi: 10.1016/j.pharmthera.2024.108655. Online ahead of print.

Authors

Hideki Yoshioka¹, Ryota Jin², Akihiro Hisaka³, Hiroshi Suzuki⁴

Affiliations

¹ Office of Regulatory Science Research, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan; Laboratory of Clinical Pharmacology and Pharmacometrics, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan.
² Laboratory of Clinical Pharmacology and Pharmacometrics, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan.
³ Laboratory of Clinical Pharmacology and Pharmacometrics, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan. Electronic address: hisaka@chiba-u.jp.
⁴ Executive Director, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan; Department of Pharmacy, The University of Tokyo Hospital, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.

PMID: 38710372
DOI: 10.1016/j.pharmthera.2024.108655

Abstract

The recent development of the first disease-modifying drug for Alzheimer's disease represents a major advancement in dementia treatment. Behind this breakthrough is a quarter century of research efforts to understand the disease not by a particular symptom at a given moment, but by long-term sequential changes in multiple biomarkers. Disease progression modeling with temporal realignment (DPM-TR) is an emerging computational approach proposed with this biomarker-based disease concept. By integrating short-term clinical observations of multiple disease biomarkers in a data-driven manner, DPM-TR provides a way to understand the progression of chronic diseases over decades and predict individual disease stages more accurately. DPM-TR has been developed primarily in the area of neurodegenerative diseases but has recently been extended to non-neurodegenerative diseases, including chronic obstructive pulmonary, autoimmune, and ophthalmologic diseases. This review focuses on opportunities for DPM-TR in clinical practice and drug development and discusses its current status and challenges.

Keywords: Alzheimer's disease; Data driven; Disease progression modeling; Drug development; Precision medicine; Temporal realignment.

Publication types

Review